The Antimicrobial Resistance (AMR) contributes to more than 700,000 deaths annually and considered a major global health catastrophe. There is an unmet need for newer potent antimicrobials due to the ineffectiveness the existing drugs against multidrug-resistant (MDR) strains of bacteria and fungi. We have invented novel platforms that help to develop a range of antimicrobial peptides and oligomers. We are based at the BSC BioNEST Bio-Incubator, Regional Centre for Biotechnology (RCB), Faridabad.
Our innovative antimicrobial Peptides and Oligomers are effective against Multidrug-Resistant (MDR) microbes.
Latest News
20/10/2022 Diwali celebration
Lighting our minds for better innovative solutions to Antimicrobial Resistance
01/09/2022 – Peptomer Therapeutics has secured BIG grant from Biotechnology Industry Research Assistance Council (BIRAC)
Project aims to develop novel oligomers as alternatives to antimicrobials, to fight global #antimicrobialresistance. Our innovative monomer technology enables controlled synthesis…
01/08/2022 Peptomer Therapeutics has secured NIDHI-PRAYAS grant
We are thankful to Department of Science & Technology (DST) and – Venture Center, Pune to support our ambition to crate…
1/06/2022 Peptomer Therapeutics has secured a startup funding from NaaViC (Agri Business Incubation Centre), ICAR-NIVEDI
To support our idea to generate novel drug delivery system to fight against drug resistant mastitis. Our innovative amino acid…
Peptomer Therapeutics secured incubator space at BSC BioNEST Bio-Incubator
We are delighted to announce that Peptomer Therapeutics has secured incubation space at BSC BioNEST Bio-Incubator, Regional Centre for Biotechnology…